50573-74-5Relevant articles and documents
Vicarious nucleophilic substitution: A dramatically shortened synthesis of 2-amino-6-nitrobenzoic acid labelled with carbon-14
Kelly, Terence P.,Filer, Crist N.,Wright, Christopher
, p. 345 - 351 (2011)
Literature preparations of 2-amino-6-nitrobenzoic acid are usually based on phthalic anhydride. In order to make [benzene-14C(U)]-2-amino-6- nitrobenzoic acid, [benzene-14C(U)]-phthalic anhydride has to be prepared in multiple steps from [14C(U)]-benzene, resulting in an unacceptably lengthy 14-step synthesis. We have been able to develop a completely different method of synthesis, producing [benzene- 14C(U)]-2-amino-6-nitrobenzoic acid from [14C(U)]-benzene in just four steps with an overall radiochemical yield of 32%.
METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
-
Paragraph 00342, (2017/02/28)
A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL; administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.
CYCLING THERAPY USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE
-
Paragraph 00203, (2017/08/04)
Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4- oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
